Yaz Lawsuits

Published on

Yaz Lawsuits

Yaz, an oral contraceptive manufactured by Bayer, was aggressively marketed despite the harmful side effects of the drug. Bayer failed to provide adequate warnings about life threatening and serious side effects. Some of the serious side effects are heart attack, stroke, deep vein thrombosis, pulmonary embolism, gallbladder disease and sudden death.

Complications with Yaz


Yaz was approved by the FDA in March of 2006 to prevent pregnancy, in October of 2006, Yaz was approved for the treatment of premenstrual dysphoric disorder and in January of 2007, Yaz was approved to treat moderate acne in patients who required birth control. They contain ethinyl estradiol, and drospirenone. This is known as a combined oral contraceptive and is more dangerous than other oral contraceptives. Drospirenone can increase potassium levels, which can result in heart problems and other side effects. People who have kidney, liver or adrenal disease are more susceptible.


Allegations with Yaz lawsuits


Bayer Healthcare Pharmaceuticals has acquired many lawsuits against them to include Yaz contraceptives. The lawsuits claim that Bayer failed to warn customers about the potential risk and side effects. They failed to complete enough testing and research before placing the drug on the market putting people at an increased risk. If the drug had been researched and tested properly, the harmful side effects and life threatening problems could have been prevented. Bayer never issued a recall or pulled the drug from the shelf after they were aware of the risk involved in taking Yaz. Yaz was marketed heavily, misused and overuse was encouraged despite the danger.


Bayer was aware of the dangers involved and did not share the information to the medical community in an effort to boast sales and profits. Women throughout the United States were essential taken advantage of in order for a pharmaceutical company to make money.

For more information please visit us at Yaz Lawsuit.

To be informed of the latest articles, subscribe:
Comment on this post